Clinical experiences often document, that a successful tumor control requires high doses of drug applications. It is widely believed that unavoidable adverse reactions could be minimized by using gene-therapeutic strategies protecting the tumor-surrounding healthy tissue as well as the bone-marrow. One new approach in this direction is the use of "Targeted Therapies" realizing a selective drug targeting to gain effectual amounts at the target site, even with drastically reduced application doses. MCF-7 breast cancer cells expressing the α v β 3 [alpha(v)beta (3)] integrin receptor are considered as appropriate candidates for such a targeted therapy. The modularly composed BioShuttle carrier consisting of different units designed to facilitate the passage across the cell membranes and for subcellular addressing of diagnostic and/or therapeutic molecules could be considered as an eligible delivery platform. Here we used the cyclic RGD-BioShuttle as a carrier for temozolomide (TMZ) at the α v β 3 integrin receptor realizing local TMZ concentrations sufficient for cell killing. The IC50 values are 12 µMol/L in the case of cRGD-BioShuttle-TMZ and 100 µMol/L for underivatized TMZ, which confirms the advantage of TMZ reformulation to realize local concentrations sufficient for cell killing. Our paper focuses on the design, synthesis and application of the cRGD-BioShuttle conjugate composed of the cyclic RGD, a α v β 3 integrin-ligand, ligated to the cytotoxic drug TMZ. The ligation was carried out by the Diels Alder Reaction with inverse electron demand (DAR inv ).
Introduction
Breast cancer is one of the most common malignancies affecting women in developed countries. [1] Approximately three out of four women with breast c a n c e r d e v e l o p m e t a s t a s e s i n b o n e w h i c h , i n t u r n , diminish the quality of life. [2] An optimal treatment concept for patients needs different therapy modalities and methods with an optimum in efficiency and the greatest possible protection. Attention should be laid on an individual and not just standardized plan of treatment for every single patient and all available therapy options should be used, such as immunotherapy, surgery or chemotherapy sensibly using cytostatic active agents with acceptable adverse reactions. I t i s r e m a r k a b l e h o w d a t e d m e d i c a l t r e a t m e n t m ethods are persistently continued [reported during the "International Brain Tumor Research Conference 2010 (http://www.kgu.de/index.php?id=4290)].
T o x i c s i d e e f f e c t s a r e d o c u m e n t e d f o r T M Z a s adverse reactions in the bone-marrow. Moreover, it is known from clinical experience, that even higher app l i c a t i o n d o s e s a r e n e c e s s a r y f o r s u c c e s s f u l t u m o r control. This approach seems obsolete now, because 'Targeted Therapy' has reached the focus of scientific interest in order to minimize such unavoidable drastic side effects. Strategies were discussed during the aforementioned meeting to protect the bone-marrow, e.g. with gene-therapeutic methods. Another interesting field is the regional chemotherapy in which cytostatic drugs are being locally applied to certain body regions. The topical application increases the a m o u n t o f a c t i v e s u b s t a n c e s i n t h e t u m o r a n d i mproves efficiency, while lowering the side effect rate at the same time.
However, many cell immanent obstacles inhibit c h e m i c a l t h e r a p y , s u c h a s t h e m u l t i d r u g r e s i s t a n c e (MDR) mediated against cytotoxic agents like TMZ, and apoptosis resistance with disruption of the complex programmed cell death pathway network. The Janicke group documented apoptosis resistant MCF-7 breast cancer cells treated with ionizing radiation, however especially breast micro-metastases are difficult to determine and even more difficult to treat effectively.
Therefore only a selective targeting of the drug can deliver an effectual amount of TMZ to its target site, even with drastically reduced application doses. H o w t o p e r f o r m t h i s i s e x e m p l a r i l y s h o w n h e r e b y targeting and controlling breast cancer cells.
Our considerations to overcome these resistance-i n d u c i n g f a c t o r s l e d t o t h e a p p l i c a t i o n o f l igands, which are target-specific for cell-typical surface receptors, as described as follows.
On these cells the α v β 3 [alpha(v)beta(3)] and α v β 5 [alpha(v)beta(5)]integrins are heterodimeric cell surface receptors which mediate adhesion between cells and the extracellular matrix. [3] The α v β 3 receptor has previously been implicated in a key role of tumor progression, metastasis and osteoclast bone resorption. [4] Integrins, the corresponding ligands, are evolutionarily old and have critical roles during developmental and pathological processes. The antibodies to α v β 3 integrin and its antagonists like arg-gly-asp (RGD)-containing peptides, including osteopontin, bone sialoprotein, vitronectin and fibrinogen are considered as efficient inhibitors which can control the tumor progression. [5] This α v β 3 integrin receptor is documented as an outstanding target in the field of tumor imaging [6] [7] [8] and is equally important as a chemotherapeutic target in the field of targeted therapy. [9] Endocytosis-mediated intracellular trafficking of ligands via the α v β 3 receptor of MCF-7 cells and the α v β 5 integrin receptor into the perinuclear region of HeLa cells is documented, which lack the functional α v β 3 receptor. [10] Interestingely HeLa cells, which express the α v β 3 integrin receptor at low level, possess lower invasive potential than MCF-7 cells. In our experiments we used MCF-7 human breast cancer cells and HeLa cervix cancer cells to investigate the new cRGD-BioShuttle as a delivery platform for targeting with TMZ in order to realize high local TMZ concentrations at the MCF-7 and HeLa cell's surfaces and, after uptake into the cells sufficient for cell killing.
This paper intends to summarize the major efforts reached thus far and focuses on the design, synthesis and application of the cRGD-BioShuttle-T M Z c o n j u g a t e . T h e w h o l e m o l ecule was synthesized via Diels Alder Reaction with inverse electron demand. It is composed of the cyclic RGD-containing the α v β 3 and α v β 5 integrin antagonist cRGD.
Cell culture
The estrogen sensitive MCF-7 adenocarcinoma breast cancer and HeLa cervix cancer cells (dkfz, tumorbank) were maintained at 37°C in a 5% CO 2 atmosphere in RPMI cell medium (Gibco, Germany) supplemented with 5% fetal calf serum (Biochrome, Germany). The cells were split twice a week.
Chemical Procedures

Synthesis of the RGD-BioShuttle
Derivatization of temozolomide
4-(6-(Pyrimidine-2-yl)-1,4-dihydro-1,2,4,5-tetrazi ne-3-yl)benzoic acid (3) was prepared from 2-cyanopyrimidine 1 and 4-cyano-benzoic acid 2 by reaction with hydrazine and then oxidized with sodium nitrite to the tetrazine derivative 4 according to the following procedure [11] . The tetrazine derivative was converted with thionyl chloride under standard conditions to the chloride 5. To this suspension of the acid chloride (2 mmol) in 20 ml CH 2 Cl 2 a solution of N-Boc-1,3-diaminopropane (2 mmol) and TEA (2 mmol) in 10 ml CH 2 Cl 2 was slowly added at 0-5°C. The resulting solution was deeply coloured and maintained for 4 h at room temperature. Then the organic phase was washed with water, followed by 1N HCl and again water. The organic layer was dried over Na 2 SO 4 [13] . The acid (2 mmol) was refluxed with thionyl chloride (10 ml) until the acid was completely dissolved. The excess of thionyl chloride was evaporated under vacuum a n d t h e r e s u l t i n g s o l i d w a s stored over NaOH.
Compound 8 (0.5 mmol) and the chloride 7 (0.5 mmol) were dissolved in 5 ml chloroform and 5 ml TEA at 0-5 °C. After 4 h at room temperature, the solution was washed with water, 1 N HCl and again with water. The organic layer was dried over Na 2 
Derivatizations of the cRGD
Synthesis of the Reppe anhydride 12
The tetracyclo-[5.4.2 1, 7 .0 2,6 .0 8,11 ]3,5-dioxo-4-aza-9,12-tridecadiene (Reppe-anhydride) 12 was prepared from 42 mg of (1Z,3Z,5Z,7Z)-cycloocta-1,3,5,7-tetraene 10 and 44 mg maleic anhydride 11 in chloroform as documented by Reppe [14] . Ligation of the cRGD-Lys(Tct) with the TMZ-tetrazine 9
Equimolar amounts of the TMZ-tetrazine conjugate 9 (1.03 mg; 2 µmol) and cRGD-Lys(Tct) 14 (7.3 mg, 2 µmol) were dissolved in aqueous solution and stored at room temperature for 24 h. The DAR inv reaction occurs at room temperature and was completed after the colour changed from magenta to yellow 
Synthesis of the cRGD-dansyl
For investigations of the cellular localization of the cRGD we functionalized the cRGD with the fluorescent dye 5-(dimethylamino)-naphthalene-1-sulfonyl, (dansyl, as shown in scheme 4/ Figure S4 ). TMZ and cRGD-BioShuttle-TMZ 15 were both dissolved in 10 % aqueous solution of acetonitrile (Sigma-Aldrich, Germany). Control studies with acetonitrile were performed to exclude potential toxic effects of this solvent.
MCF-7 and HeLa cells were grown as subconf l u e n t m o n o l a y e r s i n R P M I (control) and in RPMI containing appropriate amounts of TMZ and the cRGD-BioShuttle-TMZ 15 ( 5 0 µ M ) a n d t h e i r b e h a viour was analyzed for up to 72 hours.
Morphological evaluation
Microscopical studies of the human cancer cells w e r e c a r r i e d o u t w i t h a n Olympus inverted microscope under phase contrast conditions. The magnificat ion w a s 2 00 fol d. T he c ell s w ere ob s erv ed dur ing their culture in medium and during treatment with the different drugs.
Cellular localization of the cRGD-BioShuttle-dansyl
In order to reconfirm our data documenting an endocytotic internalization of the cRGD into the cytoplasm of α v β 3 and α v β 5 integrin expressing cells we used the confocal laser scanning microscope (CLSM)
24 hours before CLSM measurements both cell lines, the HeLa and the MCF-7 cells (5×10 5 ), were cultivated in 8-well cell culture plates (Lab-Tek) and treated with the cRGD-BioShuttle-dansyl (12.5 µM) 17.
Cytotoxic Measurements
For the toxicological characterization of the cRGD-BioShuttle-TMZ conjugate 15 as well as the cRGD and the TMZ alone as controls were added to the MCF-7 cell line's medium. The substances were incubated in a dilution series ranging from 12.5, via 25, 50, to 100 µM final concentrations up to 72 hours. The IC50 values were determined and also converted to the pIC50 scale (-log IC50) ( Table 1) .
Multiparametric Flow Cytometry Analysis
Cell size and granularity 
Results
This manuscript details the synthetic steps of our new cRGD-BioShuttle-TMZ and illustrates the cellular uptake of this newly synthesized cRGD-BioShuttle-TMZ in comparison to its controls as outlined in the respective experiments. We examined MCF-7 and HeLa cells surface targeting of these molecules with the cytotoxic drug TMZ as a cargo.
Light Microscopical Studies
In light microscopy we first investigated the cell killing effect of cRGD-Bioshuttle-TMZ 15 compared to underivatized TMZ. We achieved a rapid and high local concentration and an accumulation of TMZ on the surface of the targeted α v β 3 integrin expressing MCF-7 cells by use of the cRGD-BioShuttle as delivery and targeting platform. Figure 1 reveals the different effects of TMZ and cRGD-BioShuttle-TMZ on MCF-7 cells tested after 24 hours and 72 hours of treatment with a final concentration of 50 µM. Whereas the MCF-7 cells exhibit no formation of the squamous epithelium (B), the MCF-7 cells seem to be unimpressed by TMZ treatment (bottom row C) and resemble the untreated control (top row A) as shown in the microscopic pictures. Figure 2 indicates a clear change of the MCF-7 phenotype dependent on the concentrations of cRGD-BioShuttle-TMZ of up to 50 µM. The untreated c o n t r o l c e l l s a r e s h o w n i n t h e b o t t o m r o w f o r e a c h treatment regimen. The final concentrations of the cRGD-BioShuttle-TMZ and TMZ were from 12.5 µM, via 25 µM to 50 µM as indicated in the figure 2. A drastic cell killing of the MCF-7 cells was observed by the targeted approach, whereas the MCF-7 cells treated with underivatized temozolomide seemed to be not affected. Independent of the final TMZ concentrations used, they looked identical to the untreated control cells.
Cellular Localization Studies using Confocal Laser Scanning Microscopy -CLSM
In order to investigate the open question of the cellular localization of the cRGD-BioShuttle-TMZ we ligated a fluorescence dye to cRGD. This "BioShuttle" (cyclo RGD) connected to a fluorescent tag dansyl (as shown in scheme 4/ Figure S4 24 hours after cRGD-BioShuttle-dansyl application the fluorescence signal increased in the cytoplasm of MCF-7 and at the surface of HeLa cells, but the signal localizations remained unaltered. A nuclear located fluorescence signal was still lacking (as shown in Figure 3 , second row). The pictures from 48 and 72 hours after application demonstrate a decreased fluorescence signal suggesting a n e f f l u x o f t h e d a n s y l fluorescence dye out of the MCF-7 cell's cytoplasm, whereas in contrast the fluorescence signal at the HeLa cell's surface is unchanged (Figure 3, row 3 and bottom row).
Cellular localization of the dansyl fluorochrome
For detailed information about the cellular local i z a t i o n o f t h e d a n s y l f l u o r o c h r o m e 8 p i c t u r e s o f a z-stack were visualized in layers by CLSM. It is demonstrative, that some fluorescence signals are shown inside of the cells, but the signal is not only localized at the cell's surface but also detectable inside as pointed out in the legend of the figure 4.
Multiparametric FACS analysis
T h e m o r p h o l o g i c a l p a r a m e t e r s o f t h e F A C S analysis shows an unaltered cell size ( Figure 5 , bottom row), whereas the granularity (influenced by size and st ruct ure o f t he cel l nuc le us and b y t h e qu ant it y o f vesicles) is changed and shows an increased fraction o f m o r e g r a n u l i z e d M C F -7 cells in all treatments (TMZ, cRGD, and cRGD-BioShuttle-TMZ) in contrast to the untreated MCF-7 control cells. As demonstrated in figure 5 the granularity of MCF-7 cells is increased in cells treated with TMZ and cRGD (100 µM respect i v e l y ) . T h e m o s t c o n s p i c u o u s g r a n u l a r i t y w a s o btained after cRGD-BioShuttle-T M Z i n t h e f i n a l c o ncentration of 12.5 µM as shown in the blot of the figure  5 (right column, row 1) .
T h e t r e a t m e n t o f T M Z , c R G D , a n d cRGD-BioShuttle-TMZ in the concentrations as mentioned above shows no visible influence on the cell size of MCF-7 cells. A comparison of the flow cytometry data (Table  1 ) to the CLSM data as shown in Figure 3 right column is useful. In the image of the 24 hours time point after application with cRGD-BioShuttle-dansyl the MCF-7 cells show a clear perinuclear endoplasmic reticular located blue fluorescence signal which represents an increase in the granularity resulting f r o m t h e u n s t a i n e d e n d o p l a s m i c r e t i c u l u m s u rrounding the nucleus. As demonstrated in the Figure  5 , s e c o n d r o w , t h e c e l l s t r e a t e d w i t h 1 0 0 µ M T M Z s h o w a n i n c r e a s e d a m o u n t o f g r a n u l a r c e l l s ( 2 0 % ) compared to the untreated control with 4.5% granularity. In the sample of MCF-7 cells treated with the cRGD alone (100 µM), a cellular granularity of 33.2 % was measured. It is important to note that the MCF-7 cells treated with cRGD-BioShuttle-TMZ in an at least 8-fold reduced application dose (12.5 µM) feature the highest cell response with a cellular granularity of 34.2%.
Cellular sensitivity against cRGD, cRGD-BioShuttle-TMZ and TMZ alone -IC50 values
To measure the chemotherapeutic sensitivity against the investigated components, the TMZ, the cRGD, and the cRGD-BioShuttle-TMZ-conjugate were added to MCF-7 cells. A g a i n , t h e s u b s t a n c e s w e r e dissolved in an aqueous dilution series in culture medium in a concentration from 12.5 µM to 100 µM and applied over 72 hours. The data are presented in Table 1 . With the flow cytometry analyses we showed the high sensitivity of MCF-7 against cRGD-BioShuttle-TMZ with an IC50 value of 12.5 µM, and a much lesser sensitivity against underivatized TMZ with an IC50 of 100 µM). The MCF-7 cells treated with cRGD (12.5 up to 100 µM) were unimpressed. 
Discussion
As definitive treatments of metastases of breast cancer remain surgery, radiation therapy, and hormone therapy in the case of metastatic progress. Cyt o g e n e t i c c h a r a c t e r i s t i c s , l i k e t h e r a n g e o f t h e c h r o-mosome number between hypertriploidy and hypotetraploidy, could answer the question of the recalcit r a n c e o f m e t a s t a t i c b r e a s t c a n c e r c e l l s , e x e m p larily MCF-7 cells, against therapeutic interventions. But the t i m i n g o f t r e a t m e n t f o r a l l s t a g e s o f t h e d i s e a s e r emains controversial and new therapeutic approaches are needed [15, 16] . Encouraging results of the chemotherapeutic T M Z t r e a t m e n t i n b r a i n t u m o r s [17] remain unendorsed in the treatment of breast cancer cells.
A May 28 th 2010 search in the NCBI database PubMed with "RGD" "MCF-7" yields 26, and with "RGD" "HeLa" 89 hits. In its first 1995 publication the Huang group described inhibiting features of RGD-containing peptides against α v β 3 integrin expressing cells [18] whereas the activity of α v β 5 integrin was already documented from the Boulanger and Nemerow groups in 1993 [19, 20] .
An explanation is that the integrin α v β 3 receptor is expressed at low levels in epithelial and mature endothelial cells but is upregulated on tumor cells and tumor endothelial cells o f v a r y i n g t u m o r t y p e s i ncluding breast cancer, and therefore became considered as a prognostic factor in breast cancer [21] . It was also documented that peptide ligands containing RGD amino acid sequences h a v e a h i g h affinity for integrins and after labelling with radioisotopes, could be used for imaging α v β 3 receptor levels by PET or SPECT studies [22] . The use of RGD peptides ligated with imaging components for cell specific targeting as tumor-diagnosing tool is broadly documented [23, 24] . All these documented radioligands may be valuable for monitoring antiangiogenic therapeutics. The ligation of such therapeutically active substances to R G D p e p t i d e s c o u l d o p e n a d o o r f o r s u c c e s s f u l treatment of hardly tractable tumors like metastases expressing α v β 3 integrin. In comparison with the normal expression level of MCF-7 mammary cancer cells, α v β 3 l o w e x p r e s s i n g H e L a c e r v i x c a n c e r c e l l s were examined, which express the α v β 5 integrin and correlate with low invasiveness.
In flow cytometry, the increased relative amount of cells revealing granularity and the accession of the cell fraction featuring a clear augmentation of the granularity both might result from increased numbers of affected mitochondria, golgi apparatus or endoplasmatic reticulum. This could be explained with a pharmacologic effect of the cRGD, as well as of the TMZ alone. The BioShuttle construct containing the cRGD as targeting modul connected to the TMZ via the Diels-Alder Reaction with inverse electron demand [12] targets the α v β 3 and α v β 5 integrin MCF-7 cell surface proteins as shown in the Figure 3 . According to CLSM-pictures of the MCF-7 cells (Figure   3 ), an increased cytoplasmic coloring is indicative for a strongly increased amount of granularity in cells (R2) in the cytometric results. It is important to note that no changes in cell size could be observed.
The results of the present study demonstrate a close relationship of the reformulated drug to unanswered clinical questions as suitable solutions for the patients (as described in the introduction). Here we l i g a t e d T M Z t o t h e c R G D , a p e p t i d e -based component, which accumulates at the cell's membrane surf a c e h o l d i n g a t r e m e n d o u s p o t e n t i a l t o o p t i m i z e therapy. Enhanced local concentrations of active substances like TMZ at the cells surface, a feasible site of pharmacological action, allow expecting lower application doses with concomitantly decreased side-effects. The uptake and internalization into the cells cytoplasm is presumably documented [25] . The criteria to determine the applicability for targeting including accessibility, specificity, safety and subcellular precision are documented [26] [27] [28] [29] [30] . I n o r d e r t o fulfill all these biomedical aspects, the TMZ drug was bound as a cargo to transporter molecules (cRGD-BioShuttle-TMZ) with special chemical methods [31] . These coupling reactions however, required the reformulation of the active drug TMZ and can lead to novel properties of the TMZ. Chemoselective reaction-conditions in aqueous solution and at room temperature were obtained by chemical ligation o f f u n c t i o n a l p e p t i d e s v i a t h e D A R inv . The "click chemistry" based on the DAR inv with "inverse electron demand" resulted in an impressive efficiency as illustrated in scheme 3/ Figure S3 and is well documented [12] . This reaction enhanced the economics of the chemical reaction by the following parameters:  increase of the reaction rate,  gentle reaction conditions at room temperature, and  resulting in reaction kinetics with stoichiometric reaction partners without excess of the educts. The BioShuttle-mediated delivery and targeting platform can facilitate the transport to target cells [31, 32] . Despite the fact that the IC50 value can vary, depending on factors like the cell line, the test protocol, and the investigator, this estimation gives useful and helpful information on the relative toxicity [32] . Regarding the difference in IC50 values between the TMZ at 100 µmol/L and cRGD-BioShuttle-T M Z a t 1 2 . 5 µ m o l / L , i t b e c o m e s obvious that the cRGD-BioShuttle-TMZ offers a high potential for treatment of patients and represents an attractive enhanced drug system for upcoming clinical combined chemotherapeutic approaches [33, 34] .
